![]() |
||||||||||
Selecta II Glaucoma Laser System |
||||||||||
Assured ComplianceThe Selecta II Glaucoma Laser System is a Q-switched 532 Nd:YAG laser used in a procedure called Selective Laser Trabeculoplasty (SLT). Cleared by the U.S. Food and Drug Administration in 2001, this new system features a patented technique for performing trabeculoplasty in patients with open-angle glaucoma. It selectively targets pigmented cells and increases fluid output, lowering intraocular pressure. The Selecta II is equipped with a Q-switch that produces a 3-nanosecond high-energy beam of light, which induces the same cell replacement mechanism as traditional argon laser therapy (ALT), but without the burn. The short pulse of the laser does not allow time for heat to spread to other cells. SLT delivers just enough energy to the trabecular meshwork (TM) to target specific melanin-rich cells. This avoids thermal damage and scarring to adjacent non-melanin cells.
"SLT appears to cause no coagulative damage to the human TM, and less structural damage to the TM compared with ALT." Theresa R. Kramer, M.D., Associate Professor of Ophthalmology, Emory University, Atlanta, Georgia A 'Drop' of Light
"SLT will have a significant impact on glaucoma treatment, as well as the field of medicine." Carmen A. Puliafito, MD, Ocular Surgery News, Professor of Ophthalmology and Health Management, Tufts University School of Medicine Excellent Clinical ResultsScientific proof of its mechanisms, along with successful results showing clinical effectiveness in lowering IOP with SLT has been ongoing in the United States for five years. Details
Caution: Federal (US) law restricts Lumenis devices to sale by or on the order of a licensed practitioner. |
||||||||||
| ©2008 Lumenis Ophthalmology | ||||||||||